Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

Anti-VEGFR1/FLT1 Reference Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (1) p38 MAPK (1) VEGFR (2)
By Research Areas:	Cancer (1) Endocrinology (1) Inflammation/Immunology (1)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: Reference Standards ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) FLT3 ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-P99364

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting *VEGFR-1/FLT1* with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

HY-P990541

Anti-VEGFR1/FLT1 Antibody	VEGFR	Inflammation/Immunology
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets *VEGFR1/FLT1. Anti-VEGFR1/FLT1* Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	상품명	Target	Research Area	Image

HY-P99364

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting *VEGFR-1/FLT1* with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

HY-P990541

Anti-VEGFR1/FLT1 Antibody	VEGFR	Inflammation/Immunology
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets *VEGFR1/FLT1. Anti-VEGFR1/FLT1* Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
이메일 *

	Sorry, but the email address you supplied was invalid.